All Episodes
Oncology Brothers: Practice-Changing Cancer Discussions — 145 episodes
SURPASS-ET: FDA Approval of Ropeginterferon alfa-2b in Essential Thrombocythemia (ET)
Myelofibrosis Treatment Algorithm Discussion: Dr. Nico Gagelmann
Managing Toxicities of Therapies in Polycythemia Vera (PV) / Essential Thrombocythemia (ET)
VERIFY: FDA Approval of Rusfertide in Polycythemia Vera (PV) - Dr. Andrew Kuykendall
Polycythemia vera (PV) and Essential thrombocythemia (ET) Treatment Algorithm: Dr. Aaron Gerds
Multiple Myeloma Management - Partners in Practice with Dr. Ajai Chari Team from UCSF
HERIZON-GEA-01: FDA Approval of Zanidatamab + Tislelizumab for HER2+ Esophageai/GEJ/Gastric Adeno
Rapid Fire Rounds - Multiple Myeloma Management with Dr. Joseph Mikhael
EXCALIBER-RRMM - Iberdomide/Dara/Dex FDA Approval for R/R Multiple Myeloma: Dr. Sagar Lonial
Managing Toxicities of Androgen Receptor Pathway Inhibitor (ARPI) in Prostate Cancer
Challenging Cases in Myelodysplastic Syndrome (MDS) - Dr. Amer Zeidan
Treatment Algorithm of Myelodysplastic Syndrome (MDS) in 2026 - Dr. Thomas LeBlanc
Pancreatic Cancer Management - Partners in Practice with Dr. Tim Brown & Ms. Heather Kline
Treatment Algorithm of Late Relapsed/Refractory Multiple Myeloma (RRMM)
Treatment Algorithm of Early Relapsed/Refractory Multiple Myeloma (RRMM)
ENDURANCE Trial - Time-limited Lenalidomide Maintenance for Standard Risk Myeloma
Managing Toxicities of CAR-T in Multiple Myeloma (MM) – Drs. Caitlin Costello & Joshua Richter
Challenging Cases in Relapsed/Refractory Multiple Myeloma - Drs. Marco Davila & Krina Patel
Treatment Algorithm of Smoldering Myeloma & Newly Diagnosed Multiple Myeloma (NDMM)
EHA2026 Leukemia Highlights: OPTI-AML, KOMET-007, SENTRY
Challenging Cases in Diffuse Large B-cell Lymphoma (DLBCL) – Drs. Gilles Salles & Matt Lunning
EHA2026 Lymphoma Highlights: frontMIND, POLAR-BEAR, HD-MTX for CNS Lymphoma, EPCORE FL-1
Sacituzumab +/- Pembrolizumab FDA Approval in Triple Negative Breast Cancer: ASCENT-03 / ASCENT-04
ASCO 2026 Breast Highlights: OPTIMA, lidERA, VIKTORIA-1, KEYNOTE-522, ASCENT-03/04, TROPION-Breast02
EHA2026 Multiple Myeloma Highlights: CEPHEUS, MajesTEC-3, MajesTEC-9, MonumenTAL-3, SUCCESSOR-2
Evolving Treatment Landscape of Multiple Myeloma: Bispecifics, CAR T, and CELMoDs
Challenging Cases - Treatment of Renal Cell Carcinoma (RCC): Dr. Pedro Barata
ASCO 2026 GU Highlights & FDA Approvals with Drs. Brian Rini & Tom Powles (The Uromigos)
To hold or NOT to hold Systemic Therapy with Radiation: Dr. Nina Sanford
ASCO 2026 GI Highlights: EMERALD-3, FIGHT-302, CIRCULATE, MATTERHORN
RASolute 302 Pancreatic Cancer Study with Daraxonrasib at ASCO 2026 – Dr. Brian Wolpin
ASCO 2026 Head & Neck AND Sarcoma Highlights – Drs. Samantha Armstrong & Ari Rosenberg
Challenging Cases - Treatment of Common EGFR Mutations in Metastatic Non-Small Cell Lung Cancer
Lung Cancer ASCO 2026 Highlights: LIBRETTO-432, CROWN Update, CHRYSALIS-2, HARMONi-6
RASolute-302 with Daraxonrasib - Game Changer at ASCO 2026 in Pancreatic Cancer
ESMO Breast 2026 Highlights - VERITAC-2, PREcoopERA, PHERGain, SATEEN/BRE-354, TROPION-Breast02
Challenging Cases in Relapsed/Refractory Acute Myeloid Leukemia (AML): Dr. Joshua Zeidner
Challenging Cases in Chronic Myeloid Leukemia (CML): Drs. Fadi Haddad & Gaby Hobbs
Managing Toxicities of BRAF-MEK Inhibitors in Non-Small Cell Lung Cancer – Dr. Melissa Johnson
Treating BRAF V600E Mutated Non-Small Cell Lung Cancer (NSCLC) with Dr. Gregory Riely
Managing Toxicities of Bispecific Antibodies in Multiple Myeloma–Drs. Hamza Hashmi & Cesar Rodriguez
Managing Toxicities of EGFR Inhibitors in Lung Cancer – Drs. Azam Farooqui & Joshua Sabari
How to Treat Metastatic NSCLC with Targetable Mutations – Treatment Algorithm with Dr. Eric Singhi
How to Treat Metastatic NSCLC W/O Targeted Mutations – Treatment Algorithm with Dr. Christine Garcia
How to Treat Localized Non-Small Cell Lung cancer – Treatment Algorithm with Dr. Sanjay Popat
How to Treat Small Cell Lung Cancer (SCLC) – Treatment Algorithm with Dr. Jacob Sands
Managing Toxicities of Colorectal Cancer Drugs / Systemic Therapy – Dr. Rona Yaeger
BREAKWATER Study for BRAF V600E Mutated Colorectal Cancer – Encorafenib + Cetuximab + Chemotherapy
How to Treat Colorectal Cancer – Treatment Algorithm with Dr. Smitha Krishnamurthi
How to Treat Pancreatic Cancer – Treatment Algorithm with Dr. Shubham Pant
How to Treat Biliary Tract Cancer – Treatment Algorithm with Dr. Suneel Kamath
How to Treat Cancer of Unknown Primary (CUP) Origin – Drs. Harry Fuentes & Thor Halfdanarson
How to Treat Bladder Cancer – Drs. Stephanie Berg (Medical Oncologist) & Joshua Meeks (Urologist)
Open Evidence as an Artificial Intelligence (AI) Tool in the World of Medicine
How to Treat Renal Cell Carcinoma (RCC) in 2026 – Dr. Katy Beckermann
Evolving Treatment Landscape of HER2+ Upper GI Cancer
How to Treat Prostate Cancer Localized to Advanced Settings - Dr. Scott Tagawa
Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer
GU ASCO 2026 Highlights – CREST, POTOMAC, EV-304/KEYNOTE-B15, LITESPARK-011/022, CAPITELLO-281
Clinical Insights: Evolving Landscape of Bladder Cancer After GU ASCO 2026
Teclistamab-Daratumumab FDA Approval of MajesTEC-3 for R/R Multiple Myeloma (MM): Dr. Luciano Costa
Triple Negative Breast Cancer (TNBC) Treatment Algorithm: Dr. Tiffany Traina
Combination Approaches in PD-L1–Positive Metastatic Triple Negative Breast Cancer
HER2+ Breast Cancer Treatment Algorithm: Dr. Virginia Kaklamani
Metastatic Hormone Receptor Positive (HR+) Breast Cancer Treatment Algorithm: Dr. Kevin Kalinsky
Early Stage Hormone Receptor Positive (HR+) Breast Cancer Treatment Algorithm: Dr. Erica Mayer
Current & Future Role of Anktiva (N-803): Dr. Patrick Soon-Shiong
Trastuzumab deruxtecan (T-DXd) + Pertuzumab FDA Approval in Adv HER2 Breast Cancer: DESTINY-Breast09
Navigating Acute Myeloid Leukemia Treatment: Therapy-Related & De Novo AML with Dr. Naval Daver
Head & Neck Cancers Treatment Landscape & Algorithm – Dr. Fangdi Sun
FDA Approval of Daratumumab in High Risk Smoldering Myeloma: AQUILA by Dr. Vincent Rajkumar
ASH 2025 Multiple Myeloma Highlights – AQUILA, COBRA, TecLILLE, MajesTEC-3: Dr. Ben Derman
GI ASCO 2026 Highlights MATTERHORN, HERIZON-GEA-01, BREAKWATER, COMMIT – Dr. Rachna Shroff
ASH 2025 Lymphoma Highlights - EPCORE FL-1, CLL-17, BRUIN CLL-313, SWOG-1826: Dr. Julie Vose
ASH 2025 Leukemia Highlights PARADIGM, KOMET-007, ASC4FIRST, ASC2ESCALATE - Dr. Jorge Cortes
HER2+ SABCS 2025 Highlights DESTINY Breast-05/Breast-11, HER2CLIMB-05, PATINA: Dr. Harold Burstein
Triple Negative Breast Cancer SABCS 2025 Highlights: Dr. Rebecca Shatsky
Enfortumab vedotin + Pembro FDA Approval in Muscle Invasive Bladder Cancer (MIBC): Dr. Thomas Powles
Metastatic HR+ Breast Cancer SABCS 2025 Highlights: Dr. Hope Rugo
Early HR+ Disease SABCS 2025 Practice Changing/Informing Highlights: ALTTO, lidERA, NATALEE
Advancements and Challenges in Metastatic Colorectal Cancer Treatment
Clinical Implications of Testing HER2 and Targeted Therapies Approved - Dr. Komal Jhaveri
Toxicity Management of HER2+ Treatment Options in Upper GI Cancers – Drs. Geoffrey Ku & Shruti Patel
Current Treatment Landscape of Advanced Gastric/Esophageal/GEJ Adenocarcinoma – Dr. Rutika Mehta
Managing Toxicities of Antibody Drug Conjugates (ADCs) in Lung Cancer – Dr. Jacob Sands
Managing Toxicities of PI3K & AKT Inhibitors in Breast Cancer – Drs. Emily Gallagher & Neil Iyengar
Challenging Cases of Iron Abnormalities, Anemia or Iron Overload - Dr. Marina Beltrami
FDA Approval of Epcoritamab-Rituximab-Lenalidomide for R/R Follicular Lymphoma – Dr. Gilles Salles
Challenging Cases in Second Line & Beyond Renal Cell Carcinoma (RCC) - Dr. David Braun
FDA Approval of Durvalumab with FLOT in Resectable Gastric & GEJ: MATTERHORN by Dr. Yelena Janjigian
Challenging Cases in Breast Cancer with CDK 4/6 Inhibitors – Drs. Sara Tolaney & Adam Brufsky
Challenging Cases in Non-Muscle Invasive Bladder Cancer (NMIBC) – Drs. Shilpa Gupta & Joshua Meeks
FDA Approval of Ziftomenib (KOMET-001) in NPM1 mut Acute Myeloid Leukemia (AML) – Dr. Eunice Wang
Managing Toxicities of ROS1 Inhibitors in Non-Small Cell Lung Cancer (NSCLC) – Dr. Estela Rodriguez
Managing Toxicities of Tyrosine Kinase Inhibitors (TKI) in CML - Drs. Onyee Chan & Fadi Haddad
Lung Cancer ESMO 2025 Highlights: MDT-BRIDGE, FLAURA2, SOHO-01, Beamion LUNG-1
GI Cancer ESMO 2025 Highlights: DYNAMIC-III, PEGASUS, STELLAR-303, MATTERHORN, FORTITUDE-101
Breast Cancer ESMO 2025 Highlights: MonarchE, NATALEE, VIKTORIA1, evERA, DESTINY, ASCENT, TROPION
Current Treatment Landscape of Ovarian Cancer with Dr. Sharyn Lewin
GU Cancer ESMO 2025 Highlights: PSMAddition, Capitello-281, Potomac, Keynote-905, IMVigor011
Challenging Cases with Metastatic EGFR Mutated Non-Small Cell Lung Cancer with Dr. Eric Singhi
Managing Toxicities of CDK4/6 Inhibitors in Hormone Positive Breast Cancer - Dr. Stephanie Graff
Treating and Managing Chronic Myeloid Leukemia (CML) in 2025: Dr. Jorge Cortes
How to Manage Thrombocytopenia (ITP, HIT, DIC, TTP) - Dr. Ronak Mistry
IMforte - Maintenance Lurbinectedin + Atezo FDA Approval for Extensive Small Cell Lung Cancer (SCLC)
Exploring the role of targeted radiopharmaceutical treatment in NETs
Challenging Cases of Venous Thromboembolism (VTE) - Drs. Jennifer Vaughn & Nicolas Gallastegui
How to Treat Cutaneous Melanoma in 2025 - Dr. Omid Hamid
Treatment Algorithm of Neuroendocrine Tumors (NET) in 2025 - Dr. Thor Halfdanarson
WCLC 2025 Highlights: FLAURA2, HARMONi, ALCHEMIST with Dr. Balazs Halmos
Treating and Managing Chronic Lymphocytic Leukemia (CLL) in 2025: Dr. Mazyar Shadman
Managing Side Effects of New Treatments for Small Cell Lung Cancer
FDA Approval of Zongertinib for HER2 Mutated Non-Small Cell Lung Cancer (NSCLC) - Dr. Joshua Sabari
Latest Clinical Data for First-line Maintenance and R/R Small-Cell Lung Cancer (SCLC)
FDA Approval of Datopotamab deruxtecan (Dato-DXd) in EGFR Mutated Lung Cancer - Dr. Jacob Sands
Diagnosis and Treatment of Myelofibrosis with Dr. Raajit Rampal: Testing, Treatment, Supportive care
Managing Toxicities of TKIs and HIF-2 inhibitor in Renal Cell Carcinoma (RCC)
Myeloproliferative Neoplasms (MPN) Treatment: Polycythema Vera (PV) & Essential Thrombocythemia (ET)
Latest Advances in Tumor-Agnostic Strategies for NTRK Fusion-Positive Cancer
Challenging Cases with Relapsed/Refractory FLT3+ Acute Myeloid Leukemia (AML)
Treating Acute Myeloid Leukemia in 2025 - Induction, Consolidation, Transplant, Target Therapies
Challenging Cases with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
How to Treat Diffuse Large B-Cell Lymphoma (DLBCL) in 2025
How to Treat Early Stage Non-Small Cell Lung Cancer in 2025
ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA
FDA Approval of Telisotuzumab (Teliso-V) in c-MET Overexpression - LUMINOSITY trial
ASCO 2025 - Breast Cancer Highlights: INAVO120, SERENA-6, VERITAC-2, DESTINY-Breast09, ASCENT-04
ASCO 2025 - GI Cancer Highlights: DYNAMIC III, ATOMIC, BREAKWATER, MATTERHORN, DESTINY Gastric04
ASCO 2025 Lung Cancer Highlights: CheckMate 816, ToD, NeoADAURA, IMforte, DeLLphi 304
Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer
Managing Toxicities of EGFR Inhibitors: Afatinib, Amivantamab-Lazertinib, Osimertinib
How to treat Small Cell Lung Cancer in 2025
Treatment of Metastatic Non-Small Cell Lung Cancer With Targeted Mutations
How to Treat Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Targeted Mutations
Managing Side Effects of HER2 Targeted Therapy - Zanidatamab & Trastuzumab deruxtecan (T-DXd)
Perioperative Durvalumab FDA Approval New Standard for Muscle Invasive Bladder Cancer
Treatment Options for HER2 Positive Biliary Tract Cancers
The HER2 Diagnostic and Treatment Landscape in NSCLC
Overview of Biliary Tract Cancer & Importance of Targeted Therapies
What does it mean to be HER2 Positive in Lung Cancer
European Lung Cancer Conference (ELCC) 2025 Highlights: KEYNOTE-799, LAURA, MARIPOSA, KRYSTAL-7
FDA Approval of Cabozantinib - CABINET in pNET and epNET
How to Manage & Treat Pancreatic Cancer
How to Treat Upper Gastrointestinal Cancers in 2025 - Treatment Algorithm
ToxCheck: Managing Side Effects of Pancreatic Cancer Treatment